Early Virological Response of the First Line Combination Therapy (Pegylated Interferon I-2a and Ribavirin) in Iraqi Chronic Hepatitis C Patients and Their Psychological Adverse Effects

Dr. Vian Ahmed Wasta Ismael

Early Virological Response of the First Line Combination Therapy (Pegylated Interferon I-2a and Ribavirin) in Iraqi Chronic Hepatitis C Patients and Their Psychological Adverse Effects

Dr. Vian Ahmed Wasta Ismael * §

Contact

§ Hawler Medical University

Early Virological Response of the First Line Combination Therapy (Pegylated Interferon I-2a and Ribavirin) in Iraqi Chronic Hepatitis C Patients and Their Psychological Adverse Effects

Article Fingerprint

ReserarchID

MR13447

Key Research Insights

Synthesized scholarly intelligence & interactive research assistant

Abstract

This study was designed to assess short-term therapeutic effectiveness and psychological adverse effects of combination of pegylated interferon α-2a and ribavirin in Iraqi chronic hepatitis C patients. For this purpose fifty newly diagnosed chronic hepatitis C patients divided into three groups A, B and C, treated with equal doses of pegylated interferon α-2a (180 μg/week) and different doses of ribavirin (1200, 1000 and 800 mg/day respectively) and followed up for 12 weeks of starting treatment (prospective groups). Twenty healthy subjects were selected to be a normal group for the purpose of comparison. The results at week 12 (the time of achieving EVR) showed 100% complete EVR (cEVR) in group A, 4.4% cEVR and 5.6% null response in group B, 88.9% cEVR and 11.1% partial response in group C.

References

47 Cites in Article

Reference Format

Glyn Lewis (1994). DSM-IV. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. By the American Psychiatric Association. (Pp. 886; £34.95.) APA: Washington, DC.1994..
A Ascione,De Luca,M Tartaglione,M Lampasi,F,Di Costanzo,G Lanza,A (2010). Peg interferon alfa-2a plus ribavirin is more effective than peg interferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
Devi Oktafiani (2009). DNA extraction by Wizard® Genomic DNA Purification Kit v1.
M Cornberg,H Wedemeyer,M Manns (2002). Treatment of chronic hepatitis C with pegylated interferon and ribavirin.
G Davis (2002). Monitoring of viral levels during therapy of hepatitis C.
De Frances,Chi Fattovich,G Turrini,F Ayi,K Brugnara,C Manzato,F (2000). Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage.
Joseph Dipiro,Robert Talbert,Gary Yee,Gary Matzke,Barbara Wells,L Posey,Daniel Streetman,Darcie-Ann Streetman (2005). Book Review: Pharmacotherapy: A Pathophysiologic Approach, 7th Edition.
D Evon,D Ramcharran,S Belle,N Terrault,R Fontana,M Fried (2009). Prospective analysis of depression during peg interferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study.
M Feitelson (2003). Hepatitis C virus: from laboratory to clinic (illustrated).
Peter Ferenci,Michael Fried,Mitchell Shiffman,Coleman Smith,George Marinos,Fernando Gonçales,Dieter Häussinger,Moises Diago,Giampero Carosi,Daniel Dhumeaux,Antonio Craxì,Monique Chaneac,K Reddy (2005). Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin.
M Fried (2002). Side effects of therapy of hepatitis C and their management.
M Fried,M Shiffman,K Reddy,G Marinos,F Gonçales,D Häussinger (2002). Peg interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
M Ghany,D Nelson,D Strader,D Thomas,L Seeff (2011). An update on treatment of genotype 1 chronic hepatitis C virus infection; practice guideline by the American Association for the Study of Liver Diseases.
Marc Ghany,Doris Strader,David Thomas,Leonard Seeff (2009). Diagnosis, management, and treatment of hepatitis C: An update # † ‡.
Basil Abdallah,Nawshirwan Rashid,Shwan Tawfiq (2008). PEDIATRIC HODGKIN LYMPHOMA IN IRAQ-KRG-SULAIMANI.
L Gheorghe,M Grigorescu,S Iacob,D Damian,C Gheorghe,R Iacob (2005). Effectiveness and tolerability of pegylated interferon α-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C; from clinical trial to clinical practice.
D Greenwood,R Finch,P Davey,M Wilcox (2007). Antimicrobial chemotherapy. 5 th edi.
S Hadziyannis,H Sette,T Morgan,V Balan,M Diago,P Marcellin (2004). Peg interferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
Robin Hilsabeck,Parviz Malek-Ahmadi (2004). Neurobehavioral Correlates of Chronic Hepatitis C.
Jay Hoofnagle (2009). A Step Forward in Therapy for Hepatitis C.
Jay Hoofnagle,Kevin Mullen,D Jones,Vinod Rustgi,Adrian Di Bisceglie,Marion Peters,Jeanne Waggoner,Yoon Park,E Jones (1986). Treatment of Chronic Non-A, Non-B Hepatitis with Recombinant Human Alpha Interferon.
T Johnson,S Vasser,S Iqbal,D Clain,H Bodenheimer,Min (2004). The effectiveness of pegylated interferon and ribavirin combination therapy for chronic hepatitis C in an urban clinic setting compared to povital clinic trials.
W Kim (2002). The burden of hepatitis C in the United States.
M Kraus,A Schafer,M Scheurlen (2001). Paroxetine for the Prevention of Depression Induced by Interferon Alfa.
M Kristiansen,M Løchen,T Gutteberg,L Mortensen,B Eriksen,J Florholmen (2011). Total and cause‐specific mortality rates in a prospective study of community‐acquired hepatitis C virus infection in northern Norway.
Karen Lindsay (2002). Introduction to therapy of hepatitis C.
M Manns (2004). Adherence to combination therapy: influence on sustained virologic response and economic impact.
M Manns,J Mchutchison,S Gordon,V Rustgi,M Shiffman,R Reindollar (2001). Peg interferon alfa-2a plus ribavirin compared with interferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
M Manns,H Wedemeyer,M Cornberg (2006). Treating viral hepatitis C: efficacy, side effects and complications.
Michael Manns,Stefan Zeuzem,Ajit Sood,Yoav Lurie,Markus Cornberg,Hartwig Klinker,Peter Buggisch,Martin Rössle,Holger Hinrichsen,Ismail Merican,Yaron Ilan,Stefan Mauss,Saif Abu-Mouch,Andryes Horban,Thomas Müller,Christoph Welsch,Rongdean Chen,Rab Faruqi,Lisa Pedicone,Heiner Wedemeyer (2011). Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C.
S Mauss,T Berg,J Rockstroh,C Sarrazin,H Wedemeyer,Editors (2012). Hepatology; a clinical text.
J Mchutchison,M Fried (2003). Current therapy for hepatitis C: pegylated interferon and ribavirin.
John Mchutchison,Eric Lawitz,Mitchell Shiffman,Andrew Muir,Greg Galler,Jonathan Mccone,Lisa Nyberg,William Lee,Reem Ghalib,Eugene Schiff,Joseph Galati,Bruce Bacon,Mitchell Davis,Pabak Mukhopadhyay,Kenneth Koury,Stephanie Noviello,Lisa Pedicone,Clifford Brass,Janice Albrecht,Mark Sulkowski (2009). Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection.
H Papafragkakis,M Rao,M Moehlen,S Dhillon,P Martin (2012). Depression and pegylated interferon-based hepatitis C treatment.
Maria Rumi,Alessio Aghemo,Gian Prati,Roberta D'ambrosio,Maria Donato,Roberta Soffredini,Ersilio Del Ninno,Antonio Russo,Massimo Colombo (2010). Randomized Study of Peginterferon-α2a Plus Ribavirin vs Peginterferon-α2b Plus Ribavirin in Chronic Hepatitis C.
K Ryan,C Ray,Editors (2004). Sherris medical microbiology; an introduction to infectious diseases. 4th edi.
O Sangik,N Afdhal (2006). Antiviral therapy for treatment naïve patients with hepatitis C virus.
C Sarrazin,T Berg,R Ross,P Schirmacher,H Wedemeyer,U Neumann (2010). Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection.
Mitchell Shiffman,Fredy Suter,Bruce Bacon,David Nelson,Hugh Harley,Ricard Solá,Stephen Shafran,Karl Barange,Amy Lin,Ash Soman,Stefan Zeuzem (2007). Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV Genotype 2 or 3.
D Strader,T Wright,D Thomas,L Seeff (2004). American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C.
R Walker,O Edwards (2007). Roger Walker and Clive Edwards, <b>Clinical Pharmacy and Therapeutics (3rd Edition)</b> London: Churchill Livingstone, 2003.
B Wells,J Dipiro,T Chwinghammer,C Hamilton,Editors (2006). Pharmacotherapy Hand Book.
Roger Williams (2006). Global challenges in liver disease.
Steven Zacks,Kimberly Beavers,Dickens Theodore,Karen Dougherty,Betty Batey,Jeremy Shumaker,Joseph Galanko,Roshan Shrestha,Michael Fried (2006). Social Stigmatization and Hepatitis C Virus Infection.
S Zeuzem,C Welsch,E Herrmann (2003). Pharmacokinetics of peginterferons.
S Albumin 04 ± 0.1 4.2 ± 0.10 4.01±0.12 Body weight.
(2002). Gane, Mike 77–80, 84, 98 Le Moyne, Gertrude 119 Gariépy, Renault 59 Lévesque, René 105–6 Garric, Daniel 5, 58, 62 Levin, Charles 2, 66 Gates, Bill 13 Lévi-Strauss, Claude 6, 19, 22–5 de Gaulle, Charles 46, 100 Lewis, Wyndham 55–6 Genosko, Gary 55, 67, 110 Libermann, Ben 84 Gheerbrand, Gilles 62 Lukács, Georg 113–15 Gibson, Steve 11 Lyotard, Jean-François 49–51, 69, 110 Giradin, Jean-Claude 81 Giscard d’Estaing, Valéry 46, 103 Gould, Glenn 10, 17 McLughan, William 53 Grant, George 70 McLuhan, Corinne 9 Grigg, Russell 54 McLuhan, Eric 9 Gritti, Jules 74–5 Mandel, Ernest 111 Grock, Adrian Wettach 36, 50 Marabini, Jean 5, 58–9 Guattari, Félix 7, 17, 48–50, 105, Marchand, Philip 15, 62 110–11 Marcotte, Gilles 58, 119 Mariet, François 61–2 Marx, Karl 24, 69, 111–16 Hall, Stuart 31 Matson, Raymer B. 104 Halley, Peter 3 Mattelart, Armand 45–6 Heath, Stephen 56 Mattelart, Michèle 45 Hjelmslev, Louis 48–50 Metz, Christian 50 Hoggart, Richard 6, 17, 31–4 Michelet, Jules 21 Holland, Eugene 55 Miller, Jonathan 28, 109 Hurtubise, Claude 5 Missika, Jean-Louis 47 Huyssen, Andreas 4, 13 Molinaro, Matie 9 Monnier-Raball, Jacques 72 Iannone, M. 13 Monroe, Marilyn 59 Ionesco, Eugène 30, 57 Morin, Edgar 41–2 Moriwaki, Hiroyuki 10 Jameson, Fredric 65, 112–14 Jarry, Alfred 55 Nadeau, Maurice 18 Namer, Gérard 44 Negri, Antonio 105 Kattan, Naïm 4–5, 18 Nixon, Richard 3 Kellner, Douglas 67, 77, 84–5, 98 de Kerckhove, Derrick 9–10, 14–15, 30–1, 35, 43, 87, 119–21 Ong, Walter J. 56 Klein, Calvin 65 Orlan 11 Knockaert, Yves 58 Kroker, Arthur 2–3, 8–9, 11–12, 22, Paglia, Camille 1 28–9, 64–70, 115 Paik, Nam June 10, 30 Kroker, Marilouise 11 Paré, Jean 5–6, 22, 92, 99–103, 105 Parker, Harley 34, 81, 118 Lacan, Jacques 7, 52–4, 56–7, 63 Pasolini, Pier Paolo 104 Languirand, Jacques 103 Passeron, Jean-Claude 17 Lanoux, Armand 58–9 Paterson, Nancy 10 Lazarsfeld, Paul 50 Pauwels, Louis 120–1.

Download References

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

How to Cite This Article

Dr. Vian Ahmed Wasta Ismael. 1970. "Early Virological Response of the First Line Combination Therapy (Pegylated Interferon I-2a and Ribavirin) in Iraqi Chronic Hepatitis C Patients and Their Psychological Adverse Effects". Global Journal of Medical Research GJMR Volume 12 (GJMR Volume 12 Issue 11).

More Citation Formats

Select Citation Style:

Download Citation

GJMR Volume 12 Issue 11

Explore Journals Explore Volume Read This Issue

Journal Specifications

Crossref Journal DOI 10.17406/gjmr

Print ISSN 0975-5888

e-ISSN 2249-4618

Keywords

Not Found

Classification

GJMR Classification MSC 2010: QV 38

QV 77.2

Submission ReceivedFebruary 11, 2012
Peer Review Double Blind
Handling Editor
Accepted February 29, 2012
Published March 15, 2012

Version of record

v1.2

Issue date

January 8, 2013

Language

English

Experiance in AR

Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.

View in VR

Read in 3D

Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.

View in 3D

Article Matrices

Total Score: 152

Country: Iraq

Subject: Global Journal of Medical Research

Authors: Dr. Vian Ahmed Wasta Ismael, Prof. Dr. Kassim Al-Shamma & Dr. Hiwa Abubakir Hussein (PhD/Dr. count: 2)

View Count (all-time): 276

Total Views (Real + Logic): 5988

Total Downloads (simulated): 262

Publish Date: 2012 03, Thu

Monthly Totals (Real + Logic):

Month 1: 40 views
Month 2: 40 views
Month 3: 45 views
Month 4: 27 views
Month 5: 31 views
Month 6: 47 views
Month 7: 41 views
Month 8: 46 views
Month 9: 25 views
Month 10: 29 views
Month 11: 45 views
Month 12: 43 views
Month 13: 44 views
Month 14: 43 views
Month 15: 12 views
Month 16: 22 views
Month 17: 29 views
Month 18: 39 views
Month 19: 14 views
Month 20: 37 views
Month 21: 41 views
Month 22: 36 views
Month 23: 12 views
Month 24: 34 views
Month 25: 35 views
Month 26: 36 views
Month 27: 22 views
Month 28: 19 views
Month 29: 26 views
Month 30: 31 views
Month 31: 24 views
Month 32: 21 views
Month 33: 39 views
Month 34: 36 views
Month 35: 40 views
Month 36: 22 views
Month 37: 27 views
Month 38: 37 views
Month 39: 32 views
Month 40: 31 views
Month 41: 32 views
Month 42: 39 views
Month 43: 20 views
Month 44: 39 views
Month 45: 36 views
Month 46: 18 views
Month 47: 26 views
Month 48: 26 views
Month 49: 25 views
Month 50: 15 views
Month 51: 38 views
Month 52: 20 views
Month 53: 36 views
Month 54: 25 views
Month 55: 44 views
Month 56: 27 views
Month 57: 30 views
Month 58: 41 views
Month 59: 16 views
Month 60: 32 views
Month 61: 17 views
Month 62: 19 views
Month 63: 26 views
Month 64: 50 views
Month 65: 16 views
Month 66: 12 views
Month 67: 40 views
Month 68: 18 views
Month 69: 22 views
Month 70: 35 views
Month 71: 24 views
Month 72: 28 views
Month 73: 31 views
Month 74: 40 views
Month 75: 23 views
Month 76: 28 views
Month 77: 27 views
Month 78: 33 views
Month 79: 44 views
Month 80: 11 views
Month 81: 24 views
Month 82: 23 views
Month 83: 13 views
Month 84: 34 views
Month 85: 28 views
Month 86: 36 views
Month 87: 34 views
Month 88: 23 views
Month 89: 43 views
Month 90: 12 views
Month 91: 29 views
Month 92: 26 views
Month 93: 18 views
Month 94: 36 views
Month 95: 27 views
Month 96: 43 views
Month 97: 35 views
Month 98: 43 views
Month 99: 20 views
Month 100: 38 views
Month 101: 47 views
Month 102: 27 views
Month 103: 33 views
Month 104: 24 views
Month 105: 33 views
Month 106: 26 views
Month 107: 44 views
Month 108: 23 views
Month 109: 41 views
Month 110: 28 views
Month 111: 19 views
Month 112: 29 views
Month 113: 23 views
Month 114: 42 views
Month 115: 31 views
Month 116: 25 views
Month 117: 38 views
Month 118: 27 views
Month 119: 20 views
Month 120: 47 views
Month 121: 33 views
Month 122: 44 views
Month 123: 20 views
Month 124: 32 views
Month 125: 25 views
Month 126: 29 views
Month 127: 25 views
Month 128: 27 views
Month 129: 32 views
Month 130: 19 views
Month 131: 33 views
Month 132: 46 views
Month 133: 38 views
Month 134: 21 views
Month 135: 14 views
Month 136: 26 views
Month 137: 35 views
Month 138: 20 views
Month 139: 29 views
Month 140: 36 views
Month 141: 39 views
Month 142: 35 views
Month 143: 33 views
Month 144: 22 views
Month 145: 44 views
Month 146: 23 views
Month 147: 26 views
Month 148: 33 views
Month 149: 17 views
Month 150: 42 views
Month 151: 26 views
Month 152: 31 views
Month 153: 34 views
Month 154: 21 views
Month 155: 46 views
Month 156: 17 views
Month 157: 17 views
Month 158: 22 views
Month 159: 45 views
Month 160: 41 views
Month 161: 21 views
Month 162: 23 views
Month 163: 33 views
Month 164: 17 views
Month 165: 22 views
Month 166: 27 views
Month 167: 27 views
Month 168: 37 views
Month 169: 39 views
Month 170: 14 views
Month 171: 41 views
Month 172: 35 views
Month 173: 41 views
Month 174: 43 views
Month 175: 44 views

Total Views: 6K

Total Downloads: 262

All Trends